Stay updated with breaking news from Nasdaq Ctic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating)’s share price was up 4.4% on Monday . The company traded as high as $4.49 and last traded at $4.49. Approximately 869,000 shares changed hands during trading, a decline of 71% from the average daily volume of 3,020,629 shares. The stock had previously closed at $4.30. Wall Street […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) CEO Adam R. Craig sold 84,683 shares of CTI BioPharma stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $6.01, for a total value of $508,944.83. Following the completion of the sale, the chief executive officer now directly owns 29,440 […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) CFO David Kirske sold 60,000 shares of the firm’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $6.21, for a total transaction of $372,600.00. Following the completion of the transaction, the chief financial officer now directly owns 7,397 shares […]
CTI BioPharma (NASDAQ:CTIC – Get Rating)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a report released on Monday, TipRanks reports. They presently have a $8.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 48.70% from the company’s […]